RSCM
IMVT icon

Rock Springs Capital Management’s Immunovant IMVT Stock Holding History

Rock Springs Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-72,965
Closed -$1.18M – 105
2025
Q3 		$1.18M Sell
72,965
-148,535
-67% -$2.4M 0.07% 84
2025
Q2 		$3.54M Sell
221,500
-754,303
-77% -$11.4M 0.22% 69
2025
Q1 		$16.7M Buy
975,803
+66,700
+7% +$1.4M 0.95% 38
2024
Q4 		$22.5M Sell
909,103
-312,206
-26% -$8.86M 0.86% 42
2024
Q3 		$34.8M Buy
1,221,309
+35,655
+3% +$1.05M 1.13% 36
2024
Q2 		$31.3M Buy
1,185,654
+35,531
+3% +$1.01M 0.94% 41
2024
Q1 		$37.2M Buy
1,150,123
+166,822
+17% +$6.09M 0.94% 38
2023
Q4 		$41.4M Buy
983,301
+338,957
+53% +$12.5M 1.02% 34
2023
Q3 		$24.7M Buy
+644,344
New +$14.6M 0.66% 50
2021
Q1 		– Sell
-891,000
Closed -$41.2M – 160
2020
Q4 		$41.2M Buy
891,000
+148,551
+20% +$6.87M 0.87% 39
2020
Q3 		$26.1M Buy
742,449
+290,130
+64% +$8.73M 0.66% 48
2020
Q2 		$11M Buy
452,319
+202,319
+81% +$4.34M 0.3% 99
2020
Q1 		$3.89M Buy
+250,000
New +$3.76M 0.16% 108

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Rock Springs Capital Management's IMVT Position: Q4 2025 in Review

Rock Springs Capital Management sold out of Immunovant (IMVT) in Q4 2025, closing a stake of 72,965 shares — an estimated $1.18M sold.

Rock Springs Capital Management first reported a position in IMVT in Q1 2020 and held it in 13 quarters. The position peaked at $41.4M in Q4 2023. 196 funds tracked by Wall St. Rank hold IMVT as of Q4 2025.

  • Rock Springs Capital Management reported no remaining Immunovant position as of Q4 2025 after selling out during the quarter.
  • Rock Springs Capital Management sold 72,965 Immunovant shares in Q4 2025, an estimated $1.18M.
  • Rock Springs Capital Management first reported a position in Immunovant in Q1 2020 and held it in 13 quarters.
  • Rock Springs Capital Management's Immunovant position peaked at $41.4M in Q4 2023.
  • 196 funds tracked by Wall St. Rank held Immunovant as of Q4 2025.

Based on Rock Springs Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.